Invasion-Inhibitory Antibodies Elicited by Immunization with Plasmodium vivax Apical Membrane Antigen-1 Expressed in Pichia pastoris Yeast
- 1 March 2014
- journal article
- research article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 82 (3) , 1296-1307
Abstract
In a recent vaccine trial performed with African children, immunization with a recombinant protein based on Plasmodium falciparum apical membrane antigen 1 (AMA-1) conferred a significant degree of strain-specific resistance against malaria. To contribute to the efforts of generating a vaccine against Plasmodium vivax malaria, we expressed the ectodomain of P. vivax AMA-1 (PvAMA-1) as a secreted soluble protein in the methylotrophic yeast Pichia pastoris . Recognized by a high percentage of sera from individuals infected by P. vivax , this recombinant protein was found to have maintained its antigenicity. The immunogenicity of this protein was evaluated in mice using immunization protocols that included homologous and heterologous prime-boost strategies with plasmid DNA and recombinant protein. We used the following formulations containing different adjuvants: aluminum salts (Alum), Bordetella pertussis monophosphoryl lipid A (MPLA), flagellin FliC from Salmonella enterica serovar Typhimurium, saponin Quil A, or incomplete Freund's adjuvant (IFA). The formulations containing the adjuvants Quil A or IFA elicited the highest IgG antibody titers. Significant antibody titers were also obtained using a formulation developed for human use containing MPLA or Alum plus MPLA. Recombinant PvAMA-1 produced under “conditions of good laboratory practice” provided a good yield, high purity, low endotoxin levels, and no microbial contaminants and reproduced the experimental immunizations. Most relevant for vaccine development was the fact that immunization with PvAMA-1 elicited invasion-inhibitory antibodies against different Asian isolates of P. vivax . Our results show that AMA-1 expressed in P. pastoris is a promising antigen for use in future preclinical and clinical studies.Keywords
This publication has 44 references indexed in Scilit:
- Overcoming Allelic Specificity by Immunization with Five Allelic Forms of Plasmodium falciparum Apical Membrane Antigen 1Infection and Immunity, 2013
- Diversity Covering AMA1-MSP1 19 Fusion Proteins as Malaria VaccinesInfection and Immunity, 2013
- Genetic diversity of Plasmodium vivax and Plasmodium falciparum in HondurasMalaria Journal, 2012
- A rapid and robust tri-color flow cytometry assay for monitoring malaria parasite developmentScientific Reports, 2011
- A reliable ex vivo invasion assay of human reticulocytes by Plasmodium vivaxBlood, 2011
- A Field Trial to Assess a Blood-Stage Malaria VaccineNew England Journal of Medicine, 2011
- Long-Term Humoral and Cellular Immune Responses Elicited by a Heterologous Plasmodium vivax Apical Membrane Antigen 1 Protein Prime/Adenovirus Boost Immunization ProtocolInfection and Immunity, 2011
- Binding ofPlasmodiummerozoite proteins RON2 and AMA1 triggers commitment to invasionProceedings of the National Academy of Sciences, 2011
- Interaction between Plasmodium falciparum Apical Membrane Antigen 1 and the Rhoptry Neck Protein Complex Defines a Key Step in the Erythrocyte Invasion Process of Malaria ParasitesJournal of Biological Chemistry, 2010
- Nucleotide sequence polymorphism at the apical membrane antigen-1 locus reveals population history of Plasmodium vivax in ThailandInfection, Genetics and Evolution, 2009